炭水化物抗原125と心不全における臨床結果: システマティック・レビューとメタ解析
Seyed Morteza Pourfaraji1, Fatemeh Ojaghi Shirmard1, Dorsa Salabat1
1Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
BMC cardiovascular disorders
|August 28, 2025
まとめ
炭水化物抗原125 (CA125) 濃度の上昇は,心不全患者における死亡率と入院リスクの増加と関連しています. CA125はHFの重症度と治療への反応を評価するための貴重な非侵襲的なツールとして機能します.
科学分野:
- 心臓病科
- バイオマーカーの研究
- 臨床結果の分析
背景:
- 炭水化物抗原125 (CA125) は,心不全 (HF) の潜在的なバイオマーカーである.
- 既存の研究は,CA125レベルとHFの予後との関連を示唆しています.
- 多様なHF集団を対象とした包括的な評価が必要である.
研究 の 目的:
- 心不全患者のCA125濃度と臨床結果の関連性を評価するメタ分析を行う.
- HFにおける死亡率と入院の予後因子としてCA125を評価する.
- 疾患の重度評価と治療のモニタリングにおけるCA125の有用性を調査する.
主な方法:
- 2025年4月までのPubMed,Scopus,Web of Science,およびEmbaseの体系的な文献検索
- ランダム効果とHartung- Knapp- Sidik- Jonkmanモデルを用いた20458人の患者を含む29件の研究のメタ分析.
- PRISMAのガイドラインに従い,PROSPERO (CRD420251023141) に登録された研究です.
主要な成果:
- CA125濃度の上昇は,エンドポイントイベント (死亡またはHF入院) のリスクを有意に増加させた (HR2. 23).
- この増加したリスクは,急性 (HR1. 8),慢性 (HR2. 52) の心臓機能不全サブグループにおいて一貫していました.
- CA125とプロBNPレベル (r=0.42) の間には有意な直接的相関が認められた.
結論:
- CA125は,心不全の死亡率と入院の重要な予後要因です.
- CA125は,疾患の重症度を評価し,治療への反応を監視するための非侵襲的,オペレーター独立のツールとして機能します.
- 特に尿薬治療の指針として,HF管理のための最適なCA125カットオフレベルを確立するために,さらなる研究が推奨されています.
関連する概念動画
01:26Heart Failure III: Clinical Manifestations
42
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
42
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
57
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
57
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
213
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
213
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45